SMT C1100
SMT C11002
Phase 1 small_molecule completed
Quick answer
SMT C1100 for Duchenne Muscular Dystrophy is a Phase 1 program (small_molecule) at Summit Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Summit Therapeutics
- Indication
- Duchenne Muscular Dystrophy
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed